[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/10, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 노바티스 '졸겐스마', 종양발생 9건.."2건 벡터삽입 확인" 
[https://www.biospectator.com/news/view/30339](https://www.biospectator.com/news/view/30339)

 인제니아, 녹내장 'Tie2 항체' “머크 옵션행사 안해”
[https://www.biospectator.com/news/view/30353](https://www.biospectator.com/news/view/30353)

 노바티스, '3상실패' Lp(a) 세부결과 공개.."MACE 차이無" 
[https://www.biospectator.com/news/view/30342](https://www.biospectator.com/news/view/30342)

 종근당 아첼라, 'CETP 저해제' 비임상 발표.."2상 준비中"
[https://www.biospectator.com/news/view/30357](https://www.biospectator.com/news/view/30357)

 루닛, 사우디 국가방위부 보건의료국 'AI 솔루션' 공급
[https://www.biospectator.com/news/view/30361](https://www.biospectator.com/news/view/30361)

 CMS '약가인하 프로그램' 규정 확정.."SC, 동일제품 간주"
[https://www.biospectator.com/news/view/30346](https://www.biospectator.com/news/view/30346)

 제일약품, ‘자큐보’ 출시 2년만에 "월 처방액 100억 돌파" 
[https://www.biospectator.com/news/view/30359](https://www.biospectator.com/news/view/30359)

 이뮤노반트, '후속 FcRn' RA 2상 "28주차서 1차 도달"
[https://www.biospectator.com/news/view/30362](https://www.biospectator.com/news/view/30362)

 비만 "GLP-1 다음은?"..아밀린·UCN2 등 非인크레틴 전쟁 
[https://www.biospectator.com/news/view/30139](https://www.biospectator.com/news/view/30139)

 올릭스, '황반변성 RNAi' 뉴질랜드 2a상 "윤리심의 승인" [https://www.biospectator.com/news/view/30366](https://www.biospectator.com/news/view/30366)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/10, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)